Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPATIENS: Neoadjuvant Imlunestrant + Abemaciclib in ER+/HER2- Breast Cancer
NCT07410559Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imlunestrant in breast cancer (3 arms), sponsored by Fudan University. Primary endpoints: Objective Response Rate and Pathological Complete Response Rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07410559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410559.